Guardant Health Collaborated with AnHeart Therapeutics to Develop Guardant360 CDx and Guardant360 TissueNext for Taletrectinib
- The companies collaborated for the development, regulatory approval & commercialization of Guardant360 CDx & Guardant360 TissueNext assays as CDx for taletrectinib in the US & EU
- The focus of the collaboration is on the use of the Guardant tests for genomic profiling to identify patients who have the particular tumor mutations targeted by taletrectinib
- Taletrectinib (ROS1 inhibitor) received the BTD from the US FDA on Aug 2022 for advanced or metastatic ROS1+ NSCLC. The results showed excellent potency against crizotinib resistance, good brain penetration & intracranial antitumor activity, and favorable safety profiles in ROS1 fusion-positive NSCLC patients with few neurological adverse events
Ref: Businesswire | Image: Guardant Health
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.